(Amended: Corrects company names in the intro which were incorrectly reported earlier)
UCB SA (UCBJY), a Belgian biopharmaceutical company, on Sunday announced its agreement to buy Candid Therapeutics, a privately held clinical-stage biotechnology company, for up to $2.2 billion, aiming to strengthen its pipeline of treatments for immune-related diseases.
The deal is expected to close between late second quarter and early third quarter of 2026.
The deal includes $2 billion paid upfront and up to $200 million tied to future milestones.
The acquisition helps UCB expand its work in next-generation biologic drugs and improve treatments for conditions where the immune system attacks the body.
UCB said the financial impact will be manageable, and its 2026 outlook remains unchanged, with steady revenue and profit growth expected.
Candid's main drug, cizutamig, is an early-stage treatment designed to help the immune system target harmful cells. It is currently being tested in several Phase 1 studies for autoimmune diseases.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.